LifeSci Advisors Initiates Coverage of Navidea Biopharmaceuticals

LifeSci Advisors Initiates Coverage of Navidea Biopharmaceuticals 
Report Cites Potential of Lymphoseek(R) for Lymphatic Mapping, Which
Has an April 30, 2013 PDUFA Goal Date, and NAV4694 and NAV5001 for
the Diagnosis of Alzheimer's and Parkinson's, Respectively 
Report is Available for Download at 
NEW YORK, NY -- (Marketwire) -- 02/11/13 --  LifeSci Advisors, LLC, a
leading provider of investment research and investor relations
services in the healthcare sector, today announced that it has
initiated coverage of Navidea Biopharmaceuticals, Inc. (NYSE MKT:
NAVB), a biopharmaceutical company focused on precision diagnostic
radiopharmaceuticals. In 2011 and 2012, Navidea engaged in strategic
business development activities and carved out a strategic niche
effectively transforming itself into a pure-play precision
diagnostics company with 4 late-stage products. 
Navidea's lead product is Lymphoseek, which is a potential
"First-in-Class" targeted imaging agent for lymphatic mapping.
Following positive results from the two Phase 3 studies that hit on
all endpoints, NEO3-05 and NEO3-09, Navidea filed the Lymphoseek NDA
that was subsequently accepted by FDA. At the end of 2012, the
Company filed a Lymphoseek MAA with the European EMA. In the US,
Lymphoseek has an upcoming PDUFA goal date of April 30, 2013, and if
accepted, Navidea and its marketing partner Cardinal Health, plan to
launch with 80 direct sales representatives and an additional 400
technical liaisons, which should be sufficient to reach ~65% of
direct customers and achieve 90-95% overall market penetration. We
estimate Lymphoseek to have a global market potential of $643M. 
"Effectively de-risking the Company's business model, Navidea has
in-licensed two late-stage assets, NAV4694 and NAV5001, for the
diagnosis Alzheimer's and Parkinson's disease, respectively," said
Andrew I. McDonald, Ph.D., Managing Director at LifeSci Advisors.
"NAV4694, which was licensed from AstraZeneca, is a Fluorine-18
labeled 'Best-in-Class' radiopharmaceutical candidate in development
as an aid in the diagnosis of patients with Alzheimer's disease.
NAV4694 binds to β-amyloid deposits in the brain in order to
help diagnose patients with Alzheimer's by way of PET imaging.
NAV5001, licensed from Alseres, is a patented, novel, small molecule
agent that binds to the dopamine transporter (DaT) on the cell
surface of dopaminergic neurons and is a potential 'Best-in-Class'
agent to be viewed via SPECT imaging to identify various regions in
the brain associated with Parkinson's disease." 
In a 38-page Initiation Report by LifeSci Advisors, the clinical,
regulatory, and commercial aspects of Navidea's 4 late-stage
diagnostic assets are discussed. NAV4694 has strong performance
characteristics (rapid equilibrium, favorable CNS uptake, high
signal-to-noise ratios, and low white matter background binding) and
a very tight performance correlation to the benchmark amyloid imaging
agent C-PiB. We expect Navidea to initiate the Phase 3 NAV4694
program in early 2013. We believe that NAV4694 may have a market
potential of $1B or more. If successful, NAV4694 could generate
similar interest from potential partners as Avid
Radiopharmaceuticals' Amyvid, which was bought by Lilly for a
potential $800M. Additionally, NAV5001 has demonstrated a high
affinity for DaT and rapid kinetics, which should add to its ability
to produce clean images quickly. To date, over 600 Parkinson's
disease subjects have been treated with NAV5001 and a Phase 3 trial
under an amended SPA should be initiated in the first half of 2013.
We estimate that NAV5001 has a market potential of $1-1.5B.  
Dr. McDonald's full Initiation Report is available to download at no
cost at the LifeSci Advisors website, In
addition to this Initiation Report, LifeSci Advisors will also
provide ongoing coverage and event-based research updates on the
Company as developments occur. 
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald,
an industry veteran with more than 15 years of healthcare industry
experience. Prior to co-founding LSA, Dr. McDonald was the Senior
Biotechnology Analyst at Great Point Partners, a leading health care
investment firm with over $500 million under management. Before Great
Point, he was Co-head of Healthcare Research and Lead Biotechnology
Analyst at ThinkEquity Partners, a boutique investment banking firm
focused on growth companies. Dr. McDonald holds a Ph.D. in organic
chemistry from the University of California, Irvine, and, earlier in
his career, worked as a medicinal chemist at both Pfizer and
About LifeSci Advisors: 
LifeSci Advisors (LSA) is a leading research firm and communications
consultancy dedicated to the life sciences industry. The firm
provides strategic counsel, customized marketing communications,
comprehensive research reports and investor relations services to
companies that specialize in the discovery, development and
commercialization of drugs, drug delivery systems, medical devices
and diagnostics. To learn more about LSA, visit the company's
Important Disclosures: 
The research report described in this press release is not intended
as an offering, recommendation, or a solicitation of an offer to buy
or sell securities. The securities discussed in LSA research reports
may be unsuitable for some investors depending on their specific
investment objectives, financial status, risk profile, or particular
needs. Investors should consider LSA reports as only a single factor
in making their investment decisions and should not rely solely on
these reports in evaluating whether or not to buy or sell the
securities of the subject company. LifeSci Advisors has been
compensated by the company that is the subject of the report
described and future research reports, investor relations services,
and general consulting services. Please read each report's full
disclosures and analyst background on the LSA website,, before investing. LifeSci Advisors is not a
registered investment adviser or broker-dealer.  
Forward-looking statements: 
This press release contains forward-looking statements subject to
risks and uncertainties that could cause actual results to differ
materially from those projected. These forward-looking statements
represent LSA's judgment as of the date of this release. LifeSci
Advisors disclaims, however, any intent or obligation to update these
forward-looking statements. 
Investor Relations Contact:
Mike Rice
Phone: (646) 597-6979
Navidea Contact:
Brent Larson
Phone: (614) 793-7500
Press spacebar to pause and continue. Press esc to stop.